Hyprevention develops, manufactures and markets implantable medical devices under the STRUTPLASTY® platform, aimed at reinforcing bone in cases of fractures or impending fractures. The platform is protected by 25 patents in the United States and Europe and currently has two products on the market, with plans to expand to additional anatomical sites. Its V-STRUT© vertebral implant obtained FDA 510(k) clearance in 2020 and initial clinical cases have been described as promising. The company created a U.S. subsidiary, Hyprevention Inc., in 2021 to launch V-STRUT sales in the United States, led by CEO Cécile Vienney. In March 2022 Hyprevention raised $4.5M from Yellowstone Holding AG and existing shareholders to accelerate U.S. commercialization. Proceeds are earmarked for U.S. deployment and post-market clinical studies to continuously demonstrate product performance and address clinical needs. HYPREVENTION develops and manufactures the Y-STRUT implantable device intended to prevent hip fractures and preserve patient autonomy. Y-STRUT is used for biomechanical reinforcement of the proximal femur after low-energy trochanteric fractures and for percutaneous reinforcement of impending pathological fractures in oncology patients. The company obtained CE marking for Y-STRUT in August 2015, recorded first sales in France and signed a distribution agreement in Belgium. Founded in 2010 by Cécile Vienney and three orthopaedic surgeons, HYPREVENTION had early support from BPI France and the Regional Council of Aquitaine. At the end of 2015 the company raised €750,000 to finance the product launch and further develop its sales team and international business development. It plans to expand into Europe, South America and the Middle East and to pursue clinical trials and health-economy studies to support the hip-fracture prevention approach.

Total raised

$5M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2022